Evan Hiner, MD
Advanced Heart Failure and Transplant Cardiology · Gainesville, GANPI 1821400441
Payments from drug & device makers
What this record shows
This record is dominated by grants: $37,727 of the $48,100 with a category attached, or 78.4%. 36 manufacturers reported payments, led by Abbott at 54.0% of the total. Reporting peaked in 2020 at $39,703 and has fallen 97.0% since, to $1,199 in 2025.
Across 241 payments — averaging $199.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$26K
- Medtronic$16K
- Abiomed$1K
- Cvrx, Inc.$727
- Novartis$684
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$486
- plus $3K from 30 others
Across 3 payments — averaging $3287.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$10K
What the payments were for
- Grants$37,72778%
- Travel & lodging$1,0372%
- Food & beverage$8,96219%
- Education$3741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 38 | $25,987 |
| Medtronic(2 entities) | 15 | $16,005 |
| Abiomed | 13 | $1,139 |
| Cvrx, Inc. | 17 | $727 |
| Novartis | 24 | $684 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $486 |
| AstraZeneca | 16 | $470 |
| Johnson & Johnson | 16 | $275 |
| Boston Scientific | 7 | $271 |
| Merck | 12 | $240 |
| Inari Medical, Inc. | 3 | $233 |
| Amgen | 5 | $198 |
| Boehringer Ingelheim | 3 | $158 |
| Philips North America LLC | 3 | $139 |
| E.r. Squibb & Sons, L.L.C. | 8 | $137 |
| Pfizer | 4 | $129 |
| Edwards Lifesciences | 3 | $109 |
| Scpharmaceuticals Inc. | 5 | $93 |
| Terumo Medical Corporation | 4 | $66 |
| Bayer | 4 | $66 |
| EKOS Corporation | 3 | $61 |
| CSL Behring | 2 | $52 |
| Bridgebio Pharma, Inc. | 2 | $42 |
| Alnylam Pharmaceuticals Inc. | 2 | $39 |
| Astellas Pharma US Inc | 2 | $38 |
| United Therapeutics Corporation | 2 | $36 |
| Impulse Dynamics (USA) Inc. | 1 | $35 |
| Lexicon Pharmaceuticals, Inc. | 2 | $34 |
| Heartflow, Inc. | 1 | $25 |
| Novo Nordisk | 1 | $23 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Teleflex LLC | 1 | $21 |
| Asahi Intecc USA, Inc. | 1 | $18 |
| Akcea Therapeutics, Inc. | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Cardiac Dimensions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ensite Cardiac Mapping System$1,176
- Impella$982
- Barostim Neo System$402
- MitraClip$367
- FLOWTRIEVER CATHETER, S$314
- CoreValve Evolut$285
- HeartMate 3 Left Ventricular Dev$281
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$258
- Micra$239
- ENTRESTO$223
- IN.PACT Admiral$216
- AZURE XT DR MRI SURESCAN$160
- CardioMEMS HF System$155
- Accent Pacemaker$131
- JARDIANCE$125
- CARDIOMEMS$125
- FARXIGA$109
- CT THROMBECTOMY SYSTEM KIT$109
How this compares
$48,100 in reported general payments places this provider in the 70th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.
See all advanced heart failure and transplant cardiology providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 178 | $198,246 |
| JardianceEmpagliflozin | 178 | $162,979 |
| FarxigaDapagliflozin Propanediol | 89 | $80,655 |
| EliquisApixaban | 57 | $57,434 |
| OzempicSemaglutide | 12 | $11,399 |
| Eplerenone | 33 | $2,238 |
| Spironolactone | 226 | $1,701 |
| Valsartan | 73 | $1,681 |
| Metoprolol Succinate | 126 | $1,396 |
| Isosorbide Dinitrate | 23 | $1,178 |
| Carvedilol | 142 | $1,034 |
| Torsemide | 44 | $975 |
| Atorvastatin Calcium | 98 | $808 |
| Potassium Chloride | 57 | $706 |
| Digoxin | 18 | $612 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $684 | $198,246178 claims |
| Boehringer IngelheimJardiance | $158 | $162,979178 claims |
| AstraZenecaFarxiga | $470 | $80,65589 claims |
| PfizerEliquis | $129 | $57,43457 claims |
| Novo NordiskOzempic | $23 | $11,39912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.
Other advanced heart failure and transplant cardiology in Gainesville
- Ugochukwu EgolumGainesville$235K
- Alanna MorrisGainesville$85K
- Alison BaileyGainesville$28K
- Vikram RajeGainesville$19K
- Giancarlo AcostaGainesville$10K
- Nitya ChandraGainesville$4K
- Lawrence CharlesGainesville$4K
- Andrew DarlingtonFayetteville$1M
- Catherine MartiAthens$343K
- Darshak KariaAugusta$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.